These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3098459)

  • 1. Nocturnal pulsatile growth hormone releasing hormone treatment in growth hormone deficiency.
    Smith PJ; Brook CG; Rivier J; Vale W; Thorner MO
    Clin Endocrinol (Oxf); 1986 Jul; 25(1):35-44. PubMed ID: 3098459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency.
    Low LC; Wang C; Cheung PT; Ho P; Lam KS; Young RT; Yeung CY; Ling N
    J Clin Endocrinol Metab; 1988 Mar; 66(3):611-7. PubMed ID: 3127420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma immunoreactive GHRH and serum GH concentrations following pulsatile GHRH 1-40 administration in GH deficient children.
    Smith PJ; Pringle PJ; Brook CG; Schulster D; Rafferty B
    Clin Endocrinol (Oxf); 1987 Oct; 27(4):501-7. PubMed ID: 3124994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous growth hormone-releasing hormone augments pulsatile nocturnal GH release in GH-insufficient children, but may also raise basal GH secretion.
    Ross RJ; Kirk JM; Tsagarakis S; Trainer PJ; Ciccarelli E; Touzel R; Grossman A; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):239-48. PubMed ID: 2225481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pulsatile administration of growth hormone (GH)-releasing hormone on short term linear growth in children with GH deficiency.
    Gelato MC; Ross JL; Malozowski S; Pescovitz OH; Skerda M; Cassorla F; Loriaux DL; Merriam GR
    J Clin Endocrinol Metab; 1985 Sep; 61(3):444-50. PubMed ID: 3926806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E; Imperiale E; Boffano GM; Mazza E; Bellone J; Arvat E; Procopio M; Goffi S; Barreca A; Chiabotto P
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men.
    Hulse JA; Rosenthal SM; Cuttler L; Kaplan SL; Grumbach MM
    J Clin Endocrinol Metab; 1986 Oct; 63(4):872-8. PubMed ID: 3091629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of 1-year growth hormone (GH)-releasing hormone-(1-44) treatment on growth, somatomedin-C, and 24-hour GH secretion in six children with partial GH deficiency.
    Rochiccioli PE; Tauber MT; Coude FX; Arnone M; Morre M; Uboldi F; Barbeau C
    J Clin Endocrinol Metab; 1987 Aug; 65(2):268-74. PubMed ID: 3110202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children.
    Brain CE; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1990 Feb; 32(2):153-63. PubMed ID: 2140733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of overnight constant infusion of human growth hormone (GH)-releasing hormone-(1-44) on 24-hour GH secretion in children with partial GH deficiency.
    Rochiccioli PE; Tauber MT; Uboldi F; Coude FX; Morre M
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1100-5. PubMed ID: 3093519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone releasing hormone or growth hormone treatment in growth hormone insufficiency?
    Smith PJ; Brook CG
    Arch Dis Child; 1988 Jun; 63(6):629-34. PubMed ID: 2898924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic use of growth-hormone-releasing hormone.
    Low LC
    J Pediatr Endocrinol; 1993; 6(1):15-20. PubMed ID: 8374684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The place of intravenous GHRH 1-40 studies in the therapy of growth hormone-deficient children with GHRH.
    Smith PJ; Brook CG
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):97-105. PubMed ID: 3115638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of acute and chronic growth hormone (GH) administration on GH secretion in patients with idiopathic GH deficiency.
    Hanew K; Goh M; Sato S; Shimizu Y; Sasaki A; Aida M; Yoshinaga K
    J Clin Endocrinol Metab; 1988 Apr; 66(4):715-21. PubMed ID: 3126213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone.
    Ogilvy-Stuart AL; Stirling HF; Kelnar CJ; Savage MO; Dunger DB; Buckler JM; Shalet SM
    Clin Endocrinol (Oxf); 1997 May; 46(5):571-8. PubMed ID: 9231053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of beta 1-adrenergic blockade on the growth response to growth hormone (GH)-releasing hormone therapy in GH-deficient children.
    Cassorla F; Mericq V; García H; Cristiano A; Avila A; Boric A; Iñiguez G; Merriam GR
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2997-3001. PubMed ID: 7559887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A persistent pattern of varying pituitary responsivity to exogenous growth hormone (GH)-releasing hormone in GH-deficient children: evidence supporting periodic somatostatin secretion.
    Martha PM; Blizzard RM; McDonald JA; Thorner MO; Rogol AD
    J Clin Endocrinol Metab; 1988 Sep; 67(3):449-54. PubMed ID: 2900843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atenolol enhances nocturnal growth hormone (GH) release in GH-deficient children during long term GH-releasing hormone therapy.
    Martha PM; Blizzard RM; Thorner MO; Rogol AD
    J Clin Endocrinol Metab; 1990 Jan; 70(1):56-61. PubMed ID: 2104629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained improvement in growth velocity and recovery from suboptimal growth hormone (GH) secretion after treatment with human pituitary GH-releasing hormone-(1-44)-NH2.
    Lifshitz F; Lanes R; Pugliese M; Fort P; Perez I; Puentes S; Cervantes C; Gunczler P; Chasalow FI; Recker B
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1255-60. PubMed ID: 1430086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
    Vance ML; Kaiser DL; Martha PM; Furlanetto R; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.